Cost-effectiveness analysis of canagliflozin (CANA) versus dapagliflozin (DAPA) as an add-on to metformin (MET) in patients with type 2 diabetes mellitus (T2DM) in the united states
May 1, 2014, 00:00
10.1016/j.jval.2014.03.1448
https://www.valueinhealthjournal.com/article/S1098-3015(14)01499-5/fulltext
Title :
Cost-effectiveness analysis of canagliflozin (CANA) versus dapagliflozin (DAPA) as an add-on to metformin (MET) in patients with type 2 diabetes mellitus (T2DM) in the united states
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)01499-5&doi=10.1016/j.jval.2014.03.1448
First page :
A248
Section Title :
Diabetes/Endocrine Disorders I
Open access? :
No
Section Order :
921